Because cDC1s primarily activate CD8+ T cells 17-19, while cDC2s are required for initial priming of CD4 T cells 17, these results indicate that we should not expect a biasing toward CD4+ or CD8+ T cell activation due to uneven cDC tumor antigen acquisition. The gene discussed is CD8A; the disease is neoplasm.